Sarepta Therapeutics (SRPT) Net Margin (2012 - 2026)

Sarepta Therapeutics' Net Margin history runs 13 years deep, the most recent figure standing at 87.65% for Q1 2026.

• In Q1 2026, Net Margin rose 42328.0% year-over-year to 87.65%; the TTM figure through Mar 2026 stood at 4.82% (up 1911.0% YoY), while the FY2025 annual figure was 32.45%, down 4572.0% from the prior year.
• Net Margin was 87.65% for Q1 2026 at Sarepta Therapeutics, up from 63.86% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 194.66% in Q4 2022 to a low of 477.28% in Q1 2022.
• Historically, Net Margin has averaged 65.27% across 5 years, with a median of 12.34% in 2023.
• The sharpest annual moves came in 2022 and 2026: Net Margin plunged 36345 bps in 2022, then jumped 42328 bps in 2026.
• A 5-year view of Net Margin shows it stood at 194.66% in 2022, then sank by 95 bps to 9.85% in 2023, then surged by 170 bps to 26.56% in 2024, then tumbled by 340 bps to 63.86% in 2025, then surged by 237 bps to 87.65% in 2026.
• The last three Net Margin figures came in at 87.65% (Q1 2026), 63.86% (Q4 2025), and 45.06% (Q3 2025), per Business Quant data.